Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy

Hepatology International

Volumn 2, Issue 4, 2008, Pages 498-499

  Lakhani, Shilen ^a   Davidson, Lev ^a   Priebat, Dennis A ^a   Sherker, Averell H ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis B infection; Imatinib mesylate

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMATINIB; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CONSERVATIVE TREATMENT; DESMOID TUMOR; DRUG WITHDRAWAL; FATIGUE; HEPATITIS B; HUMAN; JAUNDICE; LABORATORY TEST; MALE; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; VIRUS REACTIVATION;

EID: 57149090698     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9099-5     Document Type: Article

References (6)

1. Lok AS, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology 2004;39(3):857-861
2. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369(9574):1731-1741
3. Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95(11):2373-2379
4. + peripheral blood progenitor cells. Blood 2004;103 (2):538-544
5. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003;17(5):978-979
6. Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006;47(1):155-157